Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | KO-2806 |
Synonyms | |
Therapy Description |
KO-2806 is a farnesyltransferase inhibitor, which may inhibit the Mtor pathway, leading to cell cycle arrest and inhibition of cell growth (Mol Cancer Ther (2023) 22 (12_Supplement): B024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
KO-2806 | KO 2806|KO2806 | Farnesyltransferase Inhibitor 4 | KO-2806 is a farnesyltransferase inhibitor, which may inhibit the Mtor pathway, leading to cell cycle arrest and inhibition of cell growth (Mol Cancer Ther (2023) 22 (12_Supplement): B024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06026410 | Phase I | Cabozantinib + KO-2806 Adagrasib + KO-2806 KO-2806 | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (FIT-001) | Recruiting | USA | 0 |